The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Abstract
BACKGROUND: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. These findings may be linked to the effect of minocycline on the glutamatergic system, through inhibition of nitric oxide synthase and blocking of nitric oxide-induced neurotoxicity. Other proposed mechanisms of action include effects of minocycline on the dopaminergic system and its inhibition of microglial activation. OBJECTIVE: To examine the efficacy of minocycline as an add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. METHOD: A longitudinal double-blind, randomized, placebo-controlled design was used, and patients were followed for 6 months from August 2003 to March 2007. Seventy early-phase schizophrenia patients (according to DSM-IV) were recruited and 54 were randomly allocated in a 2:1 ratio to minocycline 200 mg/d. All patients had been initiated on treatment with an atypical antipsychotic < or = 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/d chlorpromazine-equivalent doses). Clinical, cognitive, and functional assessments were conducted, with the Scale for the Assessment of Negative Symptoms (SANS) as the primary outcome measure. RESULTS: Minocycline was well tolerated, with few adverse events. It showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale). A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning). CONCLUSIONS: Minocycline treatment was associated with improvement in negative symptoms and executive functioning, both related to frontal-lobe activity. Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00733057.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Levkovitz et al., 2010
In the citing paper
“The sole exception was a trial29 that assessed the effects of a 6-month add-on treatment with either minocycline or placebo on cognitive impairment in young subjects in early phase schizophrenia, aged 18–35 years.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Minocycline showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“A trial performed in younger subjects with recent illness onset29 may yield more positive results than those conducted in patients with an average illness duration of >20 years (See table 1).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“add-on administration of minocycline for 22 weeks was associated with improvements in executive functions in individuals with early-phase schizophrenia [107].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [107]
Citations
Cites
Maximum Likelihood from Incomplete Data Via the EM Algorithm
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01600.x · Cited by 50,444
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Negative v Positive Schizophrenia
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,008
Executive Function and the Frontal Lobes: A Meta-Analytic Review
Alvarez, J. A., & Emory, E. (2006) · Neuropsychology Review · doi:10.1007/s11065-006-9002-x · Cited by 1,981
Cited by
Sorted by citations
Items 101–200 of 390
Immunological aspects of the treatment of depression and schizophrenia
Müller, N. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/nmueller · Cited by 80
Diverse definitions of the early course of schizophrenia—a targeted literature review
Newton, R., Rouleau, A., Nylander, A., Loze, J.-Y., Resemann, H. K., Steeves, S., & Crespo‐Facorro, B. (2018) · Schizophrenia · doi:10.1038/s41537-018-0063-7 · Cited by 82
Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia
Solmi, M., Veronese, N., Thapa, N., Facchini, S., Stubbs, B., Fornaro, M., Carvalho, A. F., & Correll, C. U. (2017) · CNS Spectrums · doi:10.1017/s1092852916000638 · Cited by 78
Müller, N. (2014) · NeuroImmunoModulation · doi:10.1159/000356538 · Cited by 78
Chue, P. S., & Lalonde, J. K. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s43404 · Cited by 77
Modulating Neuroinflammation to Treat Neuropsychiatric Disorders
Radtke, F., Chapman, G., Hall, J., & Syed, Y. A. (2017) · BioMed Research International · doi:10.1155/2017/5071786 · Cited by 80
Zhang, L., Zheng, H., Wu, R., Kosten, T. R., Zhang, X., & Zhao, J. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.005 · Cited by 75
Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia: Table 1.
Łepeta, K., & Kaczmarek, L. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv036 · Cited by 76
Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.07.006 · Cited by 75
Savitz, J. B., Preskorn, S., Teague, T. K., Drevets, D. A., Yates, W. R., & Drevets, W. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000643 · Cited by 73
Wegrzyn, D., Juckel, G., & Faissner, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105482 · Cited by 80
Clinical management of negative symptoms of schizophrenia: An update
Tsapakis, E.-M., Dimopoulou, T., & Tarazi, F. I. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.008 · Cited by 76
Anti-inflammatory signaling in schizophrenia
Meyer, U. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.014 · Cited by 72
Seki, Y., Kato, T. A., Monji, A., Mizoguchi, Y., Horikawa, H., Sato‐Kasai, M., Yoshiga, D., & Kanba, S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.09.011 · Cited by 72
Nakagawa, Y., & Chiba, K. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.234476 · Cited by 76
Morrens, M., Overloop, C., Coppens, V., Loots, E., Noortgate, M. V. D., Vandenameele, S., Leboyer, M., & Picker, L. D. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01582-y · Cited by 72
Attarzadeh-Yazdi, G., Arezoomandan, R., & Haghparast, A. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.04.008 · Cited by 70
Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans
Sofuoglu, M., Mooney, M. E., Kosten, T. R., Waters, A. J., & Hashimoto, K. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2014-5 · Cited by 70
Oya, K., Kishi, T., & Iwata, N. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2426 · Cited by 69
Panizzutti, B., Skvarc, D., Lin, S. C., Croce, S., Meehan, A., Bortolasci, C. C., Marx, W., Walker, A. J., Hasebe, K., Kavanagh, B. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065250 · Cited by 72
Kirkpatrick, B. W., Miller, B. J., García‐Rizo, C., & Fernández-Egea, E. (2013) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.kimi.031513 · Cited by 74
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders
Lisboa, S. F. D. S., Gomes, F. V., Guimarães, F. S., & Campos, A. C. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00005 · Cited by 69
The Neuroimmunology of Schizophrenia
Annya, M., Smyth, Stephen, M., & Lawrie, S. M. (2013) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2013.11.3.107 · Cited by 68
Debnath, M., Cannon, D. M., & Venkatasubramanian, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.009 · Cited by 67
Ahmed, A., Wang, L.-L., Abdel-Maksoud, S. A., Aboelgheit, A., Saeed, S., & Zhang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14450-5 · Cited by 66
Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?
Stone, J. M. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311400779 · Cited by 60
Zhang, L., Zheng, H., Wu, R., Zhu, F., Kosten, T. R., Zhang, X., & Zhao, J. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.04.004 · Cited by 59
Luca, S. N. D., Sominsky, L., Soch, A., Wang, H., Ziko, I., Rank, M. M., & Spencer, S. J. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.12.008 · Cited by 61
Dean, O. M., Maes, M., Ashton, M., Berk, L., Kanchanatawan, B., Sughondhabirom, A., Tangwongchai, S., Ng, C., Dowling, N., Malhi, G. S., et al. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.3.180 · Cited by 58
A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue
Elsayed, M., & Magistretti, P. J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00468 · Cited by 62
Psychopharmacology of the negative symptoms: Current status and prospects for progress
Davis, M. C., Horan, W. P., & Marder, S. R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.010 · Cited by 60
Möller, M., Swanepoel, T., & Harvey, B. H. (2015) · ACS Chemical Neuroscience · doi:10.1021/cn5003368 · Cited by 60
Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia
Hanson, E., Healey, K. M., Wolf, D. H., & Kohler, C. G. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0148-0 · Cited by 61
Adjunct Treatments for Schizophrenia and Bipolar Disorder: What to Try When You Are Out of Ideas
Torrey, E. F., & Davis, J. M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.4.5 · Cited by 56
Denysenko, L., Sica, N., Penders, T. M., Philbrick, K. L., Walker, A., Shaffer, S. H., Zimbrean, P. C., Freudenreich, O., Rex, N., Carroll, B. T., et al. (2018) · Annals of Clinical Psychiatry · doi:10.1177/104012371803000209 · Cited by 57
Wu, Q., Wang, X., Wang, Y., Long, Y., Zhao, J., & Wu, R. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00740-6 · Cited by 59
Büttiker, P., Weissenberger, S., Esch, T., Anders, M., Raboch, J., Ptáček, R., Kream, R. M., & Stefano, G. B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1095923 · Cited by 65
The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice
Fujita, Y., Kunitachi, S., Iyo, M., & Hashimoto, K. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.01.005 · Cited by 56
Prestwood, T. R., Asgariroozbehani, R., Wu, S., Agarwal, S. M., Logan, R. W., Ballon, J. S., Hahn, M., & Freyberg, Z. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113101 · Cited by 67
Muscatello, M. R. A., Bruno, A., Fazio, P. D., Segura‐Garcìa, C., Pandolfo, G., & Zoccali, R. A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.956082 · Cited by 58
Bringas, M. E., Morales‐Medina, J. C., Flores-Vivaldo, Y., Negrete‐Díaz, J. V., Aguilar‐Alonso, P., León‐Chávez, B. A., Lazcano-Ortiz, Z., Monroy, E., Moreno, A. R., Quirion, R., et al. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.008 · Cited by 54
Zhu, F., Zhang, L., Ding, Y., Zhao, J., & Zheng, Y. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.01.017 · Cited by 54
Anti-inflammatory medications for the treatment of mental disorders: A scoping review
Fitton, R., Sweetman, J., Heseltine-Carp, W., & van der Feltz-Cornelis, C. (2022) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2022.100518 · Cited by 53
Clifton, N. E., Morisot, N., Girardon, S., Millan, M. J., & Loiseau, F. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2845-3 · Cited by 57
Venkatasubramanian, G., & Debnath, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.04.001 · Cited by 56
Ben‐Azu, B., Omogbiya, I. A., Aderibigbe, A. O., Umukoro, S., Ajayi, A. M., & Iwalewa, E. O. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.007 · Cited by 52
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
Severance, E. G., Dickerson, F., & Yolken, R. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.005 · Cited by 52
Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits
Vakhrusheva, J., Marino, B., Stroup, T. S., & Kimhy, D. (2016) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-016-0077-2 · Cited by 53
The relationship between negative symptom subdomains and cognition
Lim, J., Lee, S.-A., Lam, M., Rapisarda, A., Kraus, M., Keefe, R. S. E., & Lee, J. (2016) · Psychological Medicine · doi:10.1017/s0033291716000726 · Cited by 53
Nettis, M. A., Pariante, C. M., & Mondelli, V. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_89 · Cited by 53
Minichino, A., Brondino, N., Solmi, M., Del Giovane, C., Fusar-Poli, P., Burnet, P., Cipriani, A., & Lennox, B. R. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.012 · Cited by 50
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015430 · Cited by 50
Ohgidani, M., Kato, T. A., & Kanba, S. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00184 · Cited by 52
Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase
Jiang, L., Wu, X., Wang, S., Chen, S., Zhou, H., Wilson, B. C., Jin, C., Lu, R., Xie, K., Wang, Q., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0573-z · Cited by 48
Soczynska, J. K., Kennedy, S. H., Alsuwaidan, M. T., Mansur, R. B., Li, M., McAndrews, M. P., Brietzke, E. M., Woldeyohannes, H. O., Taylor, V. H., & McIntyre, R. S. (2017) · Bipolar Disorders · doi:10.1111/bdi.12496 · Cited by 49
Lesh, T. A., Maddock, R. J., Howell, A. M., Wang, H., Tanase, C., Ragland, J. D., Niendam, T. A., & Carter, C. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0428-y · Cited by 49
The effect of minocycline on symptoms in schizophrenia: Results from a randomized controlled trial
Weiser, M., Levi, L. W., Burshtein, S., Chiriță, R., Cirjaliu, D., Gonen, I., Yolken, R. H., Davidson, M., Zamora, D., & Davis, J. M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.10.023 · Cited by 48
Volk, D. W. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.019 · Cited by 47
The influence of the glutamatergic system on cognition in schizophrenia: A systematic review
Thomas, E. H. X., Bozaoglu, K., Rossell, S. L., & Gurvich, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.005 · Cited by 47
Inflammation in individuals with schizophrenia – Implications for neurocognition and daily function
Kogan, S., Ospina, L. H., & Kimhy, D. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.09.016 · Cited by 47
Kroken, R. A., Løberg, E., Drønen, T., Grüner, R., Hugdahl, K., Kompus, K., Skrede, S., & Johnsen, E. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00011 · Cited by 49
Profile of minocycline and its potential in the treatment of schizophrenia
Zhang, L., & Zhao, J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s64236 · Cited by 45
Guessoum, S. B., Strat, Y. L., Dubertret, C., & Mallet, J. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109862 · Cited by 50
Levkovitch-Verbin, H., Waserzoog, Y., Vander, S., Makarovsky, D., & Piven, I. (2014) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-014-2588-4 · Cited by 44
Self-citationThe Psychopharmacology Algorithm Project at the Harvard South Shore Program
Osser, D. N., Roudsari, M. J., & Manschreck, T. C. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e31827fd915 · Cited by 45
Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms
Kelly, D. L., Vyas, G. R., Richardson, C. M., Koola, M. M., McMahon, R. P., Buchanan, R. W., & Wehring, H. J. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.08.005 · Cited by 44
Marini, S., Berardis, D. D., Vellante, F., Santacroce, R., Orsolini, L., Valchera, A., Girinelli, G., Carano, A., Fornaro, M., Gambi, F., et al. (2016) · Mediators of Inflammation · doi:10.1155/2016/3476240 · Cited by 48
The antidepressant impact of minocycline in rodents: A systematic review and meta-analysis
Reis, D. J., Casteen, E. J., & Ilardi, S. S. (2019) · Scientific Reports · doi:10.1038/s41598-018-36507-9 · Cited by 45
Al‐Hakeim, H. K., Almulla, A. F., & Maes, M. H. J. (2020) · Neurotoxicity Research · doi:10.1007/s12640-019-00112-z · Cited by 49
Dieset, I., Hope, S., Ueland, T., Bjella, T. D., Agartz, I., Melle, I. S., Aukrust, P., Røssberg, J. I., & Andreassen, O. A. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.06.040 · Cited by 43
Tremblay, M.-È. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100301 · Cited by 42
Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41
Missing and Possible Link between Neuroendocrine Factors, Neuropsychiatric Disorders, and Microglia
Kato, T. A., Hayakawa, K., Monji, A., & Kanba, S. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00053 · Cited by 43
Chang, C.-H., Lane, H., Tseng, P., Chen, S.-J., Liu, C., & Lin, C. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118822157 · Cited by 42
Aminov, R. I. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00241 · Cited by 40
Liaury, K., Miyaoka, T., Tsumori, T., Furuya, M., Hashioka, S., Wake, R., Tsuchie, K., Fukushima, M., Limoa, E., Tanra, A. J., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.12.017 · Cited by 40
Successful Use of Add-on Minocycline for Treatment of Persistent Negative Symptoms in Schizophrenia
Jhamnani, K., Shivakumar, V., Kalmady, S. V., Rao, N. P., & Venkatasubramanian, G. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.11120376 · Cited by 40
Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System
Dinesh, A. A., Islam, J., Khan, J., Turkheimer, F., & Vernon, A. C. (2020) · CNS Drugs · doi:10.1007/s40263-020-00765-x · Cited by 40
Foss‐Feig, J. H., McPartland, J. C., Anticevic, A., & Wolf, J. M. (2015) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-015-2539-x · Cited by 45
Coptidis Rhizoma Prevents Heat Stress-Induced Brain Damage and Cognitive Impairment in Mice
Moon, M., Huh, E., Lee, W., Song, E., Hwang, D., Lee, T. H., & Oh, M. G. (2017) · Nutrients · doi:10.3390/nu9101057 · Cited by 39
Glia‐related genes and their contribution to schizophrenia
Wang, C., Aleksić, B., & Ozaki, N. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12290 · Cited by 39
Pharmacological Strategies for Enhancing Cognition in Schizophrenia
Barch, D. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_39 · Cited by 38
The impact of inflammation on neurocognition and risk for psychosis: a critical review
Kogan, S., Ospina, L. H., Mittal, V. A., & Kimhy, D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01073-2 · Cited by 38
Vingerhoets, W. A. M., Bloemen, O., Bakker, G., & van Amelsvoort, T. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00157 · Cited by 39
Adjunctive minocycline for major mental disorders: A systematic review
Zheng, W., Zhu, X., Zhang, Q., Cheng, G., Cai, D.-B., He, J., Ng, C. H., Ungvari, G. S., Peng, X.-J., Ning, Y., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119858286 · Cited by 38
Maldonado‐Ruiz, R., Cárdenas‐Tueme, M., Montalvo-Martínez, L., Vidaltamayo, R., Garza‐Ocañas, L., Reséndez‐Pérez, D., & Camacho‐Morales, A. (2019) · Nutrients · doi:10.3390/nu11061241 · Cited by 36
Glutamatergic agents for schizophrenia: current evidence and perspectives
Zink, M., & Correll, C. U. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1040393 · Cited by 36
An emerging role of cGMP in the treatment of schizophrenia: A review
Shim, S. S., Shuman, M. D., & Duncan, E. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.015 · Cited by 35
Neuroinflammation and oxidative stress in schizophrenia: are these opportunities for repurposing?
Ansari, Z., Pawar, S. R., & Seetharaman, R. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2006514 · Cited by 35
Kato, T. A., Watabe, M., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., Utsumi, H., & Kanba, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040461 · Cited by 34
Drug repurposing and emerging adjunctive treatments for schizophrenia
Bumb, J. M., Enning, F., & Leweke, F. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032248 · Cited by 33
Mahmoud, M. E., Fereig, R. M., & Nishikawa, Y. (2017) · Infection and Immunity · doi:10.1128/iai.00007-17 · Cited by 35
Dobric, A., Luca, S. N. D., Spencer, S. J., Bozinovski, S., Saling, M. M., McDonald, C. F., & Vlahos, R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108017 · Cited by 35
A case of methamphetamine use disorder treated with the antibiotic drug minocycline
Tanibuchi, Y., Shimagami, M., Fukami, G., Sekine, Y., Iyo, M., & Hashimoto, K. (2010) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.12.005 · Cited by 33
Pérez‐Gómez, A., Carretero, M., Weber, N., Peterka, V., To, A., Titova, V., Solis, G. M., Osborn, O., & Petrascheck, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07684-y · Cited by 35
Anti-Inflammatory Diets and Schizophrenia
Yun, H. S., & Yang, S. J. (2020) · Clinical Nutrition Research · doi:10.7762/cnr.2020.9.4.241 · Cited by 35
Müller, N., & Bechter, K. (2013) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2013.04.004 · Cited by 37
Watabe, M., Kato, T. A., Monji, A., Horikawa, H., & Kanba, S. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2509-8 · Cited by 33
Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
Sendt, K.-V., Giaroli, G., & Tracy, D. K. (2012) · ISRN Pharmacology · doi:10.5402/2012/427267 · Cited by 34
Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen
Salacz, M. E., Kast, R. E., Saki, N., Brüning, A., Karpel‐Massler, G., & Halatsch, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100407 · Cited by 33
Metadata
- Authors
- Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S.
- Affiliations
- Shalvata Mental Health Center (IL)
- Corresponding author
- Levkovitz, Yechiel
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-11-03
- Volume
- 71
- Issue
- 02
- Pages
- 138-149
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084588595
- Cited by
- 387
- References
- 112
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 26 · 2019: 22 · 2018: 26 · 2017: 15 · 2016: 33 · 2015: 42 · 2014: 34 · 2013: 44 · 2012: 27
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- minocycline, early-phase schizophrenia, negative symptoms, cognitive impairment, executive function, adjunctive therapy, glutamatergic system, nitric oxide synthase inhibition, microglial activation, atypical antipsychotics, Scale for the Assessment of Negative Symptoms
- MeSH terms
- Adolescent, Adult, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Minocycline, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
